Thank you so much, and welcome to our full-year conference call after today's release of our annual report 2025, including our outlook for the new financial year. One personal note from myself.

After 3.5 years with SUSS, in total four annual reports, two capital market days, and, yeah, countless investor and analyst interactions, today marks my final conference call with SUSS. While I truly love the company, I have decided to take on an exciting new role in a different listed German company as of May.

April 24th will be my last day at SUSS, and my colleague Florian Mangold will continue to be available to you as your point of contact. Now back to the official part.

As you probably know from earlier calls, this call is being recorded and considered as copyright material. It cannot be recorded or rebroadcast without permission, and participating in this call implies your consent to this procedure.

Please be aware of our safe harbor statement on page two of the slide deck. It applies throughout the conference call.

Now I hand over to Burkhardt, our CEO, for some opening remarks, followed by our CFO presenting the financial development. Burkhardt, please.

Sven, many thanks, and also thanks for your great contribution over the past 3.5 years. We really enjoyed you having on board, and I'm sure you will have an exciting future ahead of you.

Thanks a lot from my side. Let's now start with an overview on the key financials for 2025.

Our order intake ultimately came in at €354 million. More on this shortly, with a particular focus on the fourth quarter.

Revenue recorded at €503 million, once again, a double-digit growth and exceeding half a billion for the first time. Profitability, with a gross profit margin of 35.7% and an EBIT margin of 13.1%, we came short of our initial margin expectations.

However, we did meet our most recent guidance. Now a few more words on revenue.

€503 million marks another record revenue figure and an all-time high for SUSS. Even more important, we have increased revenue over the past two years from around €300 million to €500 million, an increase of €200 million.

SUSS is now a significantly larger and more capable company. We are a growth company, and we intend to resume this growth in the mid-term.

Regarding order intake, in November, I stated that we could achieve €100 million in order intake in the fourth quarter. We now can confirm an order intake of €117.5 million.

The book-to-bill ratio was thus around one. Both segments contributed to the improved order situation, with AI being the dominant driver both in terms of HBM and CoWoS.

Further good news, this positive momentum has continued into the first quarter of 2026. Now on profitability.

We explained the deviation from our original plans during the Q3 conference call. As we said on the Capital Markets Day in mid-November, we introduced the new product generations and innovative solutions to achieve a substantial improvement in margins.

That's why we are very much looking forward to the next two to three years and the multiple launches we have lined up. Now let's take a look at the performance of our two segments.

First, Advanced Backend Solutions. Order intake was approximately €25 million lower than in the previous year and was distributed fairly evenly across the three product lines: imaging, coating, and bonding.

Demand for our imaging systems, specifically for UV projection scanner used in CoWoS process, remained strong. Demand for bonding solutions was lower than in previous year, but has improved since the fourth quarter.

Revenue grew by 10.7% to around €350 million, while bonding was below 2024. Imaging and coating systems contributed the most significant growth, each posting an increase of more than 50% compared to the previous year.

Profitability was significantly lower than in previous year, primarily due to weaker product and customer mix, strong growth in imaging and coating, and the frequently mentioned increased temporary ramp-up support provided to our customers for already installed tools as well as the establishment of our new production facility in Taiwan. Now to Photomask Solutions.

Order intake of approximately €80 million was significantly down by €43.5 million from the previous year. Out of this number, €31 million was due to lower orders from Chinese customers.

However, Q4 showed an improved trend versus Q2 and Q3. Revenue growth of 17.3% to over €150 million is very encouraging.

Thanks to our improved operational capabilities, we have further significantly reduced our backlog and accelerated the completion of customer projects. Higher sales volume and an improved product and customer mix also led to a 5 percentage points increase in the gross profit margin and an 8 percentage points increase in the EBIT margin.

Now let's zoom in on the fourth quarter of 2025. I already mentioned the positive order intake of €117.5 million, reversing the negative trend of the first three quarters.

Out of this amount, €92 million was attributed—difficult word—to the Advanced Backend Solutions and €25.5 million to Photomask Solutions. We once again received several orders for our UV projection scanner for CoWoS process as well as for HBM-related follow-up orders, particularly for one of our memory customers.

Orders for our mask aligner from customers in mainstream applications have also improved significantly. It may still be too early to speak of a turnaround in this business, but this was certainly a strong intake quarter.

Revenue of €190 million was almost unchanged from the third quarter of €118 million. This demonstrates our significantly greater stability when it comes to executing customer projects.

Gross profit margin remained low at 34.9%, though it improved slightly compared to the third quarter where we had 33.1%. EBIT margin was 9.8%, which was slightly lower than Q3, but still better than we originally had expected.

To wrap up the first part, here is a look at our new production facility in Zhubei, Taiwan, which is already fully operational. Following the opening ceremony at the end of October, all relocation work has since been completed.

As planned, we returned all existing locations to our landlords by the end of February. We delivered the first tool made in Zhubei, a UV projection scanner, to our customer already in February.

Production is now in full swing, as you see on this picture. About 10 tools were built in Zhubei during the first quarter in 2026.

Further capacity increase is under preparation. Q1 '26 is therefore also the last quarter in which the P&L will be impacted by the implementation of the new site.

With that, I hand over to Cornelia for some details on our financial development.

Thank you, Burkhardt, and also a warm welcome from my side to all of you. Here you see our key financial figures.

I would like to point out that the previous-year figures have been adjusted due to accounting changes made in the connection of the preparation of the 2025 consolidated financial statements. These changes are explained in detail in the notes in our annual report, which has been published today.

The adjustments for fiscal year 2024, in short, are: a sales adjustment amounted to plus a half a million, gross profit was adjusted by minus €1.5 million, and EBIT by minus €0.5 million, and net income was adjusted by €0.4 million. In a nutshell, the main changes are based on a more detailed approach to revenue recognition.

In particular, installation service following the delivery of our tools and upgrades are no longer recognized on a point-in-time basis, but rather on a period basis. This is from shipment to final acceptance by the customer.

The second significant change was made to the provision for the equity-based compensation, which is now recognized on a pro rata temporis basis over the entire four-year period, the vesting period, rather than at the time of the grant of the virtual shares at their estimated value. This resulted in an adjustment of plus €1.2 million in EBIT.

Now let's have a look on our financials here on the screen. The order book was €266.8 million at the end of 2025.

The vast majority of these orders will be produced, delivered, and recognized as revenue throughout 2026. Expenses for selling, administration, and R&D increased from roughly €100 million to €118 million in 2025.

The main reasons were an increase in R&D, plus €7 million spending to support several product and technology development projects, and for IT and digitalization projects, such as the mitigation of our ERP system. That's not all.

There are some other systems we introduced. The full cost impact of new hires made in 2024 has the full impact in 2025.

Net profit amounted to €46.1 million in 2025, down from €110 million in 2024, when the sale of the micro-optics business had resulted in a significant one-time gain. Cash and cash equivalents were at €98.7 million, and compared to 2024, reduced by €33.5 million.

This mainly because of a significant lower prepayments from our customers, and of course, due to our CapEx in 2025. Net cash amounted to €49.1 million in 2025, and this is because of the deduction of the leasing liability from the lease agreement for our new Zhubei site, which caused this decline.

Free cash flow from continuing operations was €20.6 million in 2025, and in total at -€26 million. The fourth quarter was cash flow positive at €5.6 million, but that was not enough to bring the figure back to zero.

As our dividend policy is based on free cash flow and is designed for a payout of 20% to 40% of this figure, a dividend of 4 cents per share will be proposed to the Annual General Meeting in June. CapEx increased to €23.2 million in 2025, driven in particular by our new site in Zhubei.

Now let's move to the development of our main financial KPIs over the fiscal year. Please be aware of that the '25 quarterly figures are as reported.

This means they are not restated. In our reporting in 2026, all prior-year figures will be restated.

Burkhardt has already mentioned the significant improvement in order intake in the fourth quarter of 2025. While this can certainly be attributed to seasonal factors and a traditionally strong fourth quarter, it is all the more important that we are able to confirm this improved demand in the coming months.

We have already discussed profitability in the past. This overview clearly shows that profitability came under pressure, particularly in the second half of the year.

The decline in the second half of the year is not unexpected. The weak order intake in the first two quarters and the shift and its composition, as well as some non-recurring items and extra costs, are clearly evident here.

To achieve a significant improvement, we are working on new, higher-margin product solutions, which will only begin to gradually impact the P&L starting in 2027. In both segments, we have an order intake trend reversal, with strong bookings in both divisions versus previous quarters, and this trend continues in the first quarter.

Photomask Solutions benefited in the fourth quarter from product and customer mix, also in connection with upgrade and service business, and from some currency gains. The fourth quarter of Advanced Backend Solutions, a lower top line in the fourth quarter than in the third in combination with very negative product mix affected gross profit margin and EBIT margin.

There were a lot of UV scanner, but we had the lowest amount of bonders in the fourth quarter. As the double rental costs for the new fab in Zhubei affected the result.

In addition, write-offs for cleanroom equipment in our old Hsinchu site, which cannot be used in our new fab in Zhubei, this impacted the result in the fourth quarter. Also R&D expenses raised in the fourth quarter to support future growth projects.

The R&D expenses also left their mark on the fourth quarter, especially projects for LF chamber improvements and for a CoPoS project. On this slide, you see our order intake by segments and regions.

The order intake by region shows a familiar pattern. The APAC region once again accounted for the largest share of new orders at around 77%, with Taiwan as a dominant contributor.

The remainder was distributed relatively evenly between EMEA and Americas. Now I would like to present the main balance sheet developments.

Total assets increased by €7.6 million. For the non-current assets, the main driver was the Taiwan expansion with the right-of-use asset and CapEx for the interior layout of the building in Zhubei.

As well, there were some CapEx in Europe, around €8 million, mainly in Germany. In current assets, we have a decrease by €54 million to a total volume of €386.7 million.

Inventory declined by €39.1 million on a year-on-year basis and amounted to €171.6 million at the end of '25. Contract assets and trade receivables in total increased by €20.6 million.

Cash and cash equivalents decreased, as I said, by €37.5 million, and of course, due to free cash flow of -€26 million, and of course, of the dividend payments in the last year and some repayments of our financial debt together in the amount of around €10 million. On the liability side, the main changes already happened in the second quarter with the inclusion of the leasing liabilities from the Taiwan site.

In non-current liabilities, the main driver was this lease liability for the Zhubei site. Current liabilities decreased at the same time, -€60.2 million.

Here, the major drivers were lower prepayments from our customers, who supported last year's steep ramp, and now we have less orders from customers which usually accept prepayments. Equity increased by €32.5 million, and equity ratio was at 62.2% at the end of December '25, which means that we have improved the equity ratio by 5.6 percentage points.

Net income contributed is €46.1 million, and other comprehensive income and dividend payments amounted to -€13.7 million. Finally, I would like to give you a brief overview of the new syndicated loan which we announced back in mid-February.

Despite the current healthy liquidity position, it is very important for us as a company to increase our financial flexibility to finance for the growth and to maintain sufficient reserves to cover industry-typical fluctuations. We achieved this with a new syndicated loan agreement, as the volume has roughly doubled to €115 million, thereof €85 million for revolving credit facility and €30 million for guarantees.

The new contract has a term of five years with two optional one-year extension periods. We are now even better positioned to support our growth plan and have sufficient buffer against industry-specific fluctuations as well as against a general deterioration in economic conditions and economic cycles.

Finally, we had significantly reduced the liquidity risk. Now I give back to Burkhardt.

He will present the outlook for 2026.

Thanks, Cornelia. As you said, I now like to come to the guidance overview.

As said before, 2026 will be a transition year. After that, we expect to resume our growth path.

Forecasted sales range of €425 million to €485 million, indicating a decline of 9.6% at the midpoint of the range. We see a broadly stable gross profit margin of 35% to 37%, but a declining EBIT margin of 8% to 10%.

On the next three pages, I will provide a bit more color on all three KPIs. First, on the sales guidance of €425 million to €485 million.

When we compare the starting points for 2024, 2025, and 2026, obviously, we are beginning the year with a significantly lower order book. You see a detailed comparison on the right side.

As a result, visibility at the start of the year is lower. Therefore, we decided to expand the guidance corridor from previously €40 million to €60 million.

The extent of the revenue decline compared to 2025 will highly depend on the volume of orders we will receive in the first half of 2026. Thanks to our improved operational flexibility and shorter lead times, we will be able to execute the majority of the orders between January and June within the same year and recognize them as revenue.

On gross profit margin, we forecast 35% to 37%, and thus are broadly stable in our expectation. As said before, in the financial year 2026, we will be offering more or less the same portfolio as in 2025.

For portfolio-driven, substantial improvements, we will launch and ship our new product solutions in the next two years. A change in the product and customer mix could still affect margins during the year, depending on the order intake from the first half of the year and beyond.

For example, higher demand for bonding solutions would generally be beneficial for us. Then there are various effects that are likely to neutralize each other.

On the positive side, fewer one-off events, such as the establishment of a new site in Taiwan and a more normalized ramp-up support for our customers for already installed tools. On the negative side, the impact of the expected decline in revenue on the fixed cost coverage.

Finally, our EBIT margin, which is forecasted to a range of 8% to 10%. We had already explained in the Capital Markets Day that the expected decline in revenue is likely to impact the EBIT margin development.

In that regard, I don't think the guidance came as much of a surprise. A few analysts had already placed their estimates within that range.

Here is what we do expect to happen. First, lower sales volume, combined with a broadly stable gross profit margin, will weight on profitability.

We have made a conscious decision not to reduce the R&D budget despite the lower revenue forecast. On the contrary, we actually expect an increase in this area as we are setting the base for future growth in the coming years.

At the same time, we expect only a slight increase in sales and administrative expenses, and I can assure you that we will continue to strictly manage those budgets. Now some words on the expected development in our two segments.

First, Advanced Backend Solutions. Expected sales decline of roughly 10% versus '25 is expected.

Slight increase in gross profit margin and a broadly stable EBIT margin as lower business volume will have an impact on profitability. We anticipate the following trends in the market demand: Imaging systems, there we see a stabilization of the strong 2025 level, provided there is continued CoWoS-related demand for additional UV projection scanners.

Coating, we see a slight improvement expected, provided that the mainstream business picks up alongside a continued strong packaging and OSAT business. On bonding, significant improvements versus 2025 are expected as HBM customers commit to add more capacity again after a temporary digestion period which we experienced last year.

Secondly, on Photomask Solutions. We have similar sales expectations as in the backend unit, with roughly 10% versus 2025.

Profitability is expected to decline as a result of the lower sales volume. On the market outlook, I can comment that we expect an improved order situation as high demand for semiconductors, again driven by AI, requires additional front-end equipment—see also the strong ASML order trend—and consequently, also additional mask cleaning equipment.

Preparation of customers for the introduction of High NA also can play a role. Potential for additional momentum from the launch of three new solutions, like the high-end mask cleaner, the mid-end mask cleaner, and the first wafer cleaner addressing the 200 market, can also give us a boost.

When looking at our guidance for 2026, some might think that this year represents a step backwards for SUSS. I personally don't see it that way.

As said, 2026 is a transitional year, or rather a year of preparation for further growth and a substantial improvement in margins by 2030. These goals, which we presented in November Capital Markets Day, remain unchanged and recently are even getting tailwinds.

Thanks to a strong focus on R&D and the development of new, innovative solutions and next-generation products for selected, faster-growing markets, 2026 is an important year and a necessary stepping stone into our bright future. With that, we are opening the floor to your questions.

Hi, good afternoon. Thanks for taking my question.

Burkhardt, I just want to check whether you can give us any indication on how you would expect your sales and gross margin to trend through the year. Is it possible that Q1 is your low point for both sales and gross margin, and then you will see a gradual improvement from there?

Would that be a reasonable assumption, or any other color how you see the first half versus the second half develop would be great. I have a small follow-up.

Menon, that's a really good question, and of course, you're spot on. We see really us hitting in Q1 as a low point of the effects we saw last year.

Remember, we had a three-quarter declining order intake, and it started showing, of course, in the last quarter of last year, and it will extend into the first quarter. However, this is offset, of course, with a reversed trend in order intakes, which, of course, will take a couple of quarters to materialize in improved situation.

We think we are approaching the bottom here and will climb back from there.

Understood. Then I was in Taiwan recently, and there's some talk in the Taiwan market about TSMC looking to localize their equipment, especially on the back end, where possible, and working with some of the local companies.

I was just wondering whether you have any thoughts on that. Do you see this as a potential threat, or is this mainly in areas where SUSS is not involved right now?

No, I see that as an opportunity, because we are local at the doorstep of Taiwan with our main production site. That's, by the way, also where we are developing our next-generation UV scanner, also in Taiwan.

In that sense, you could even call us a local company. At least on those products we are designed in, I think we have a fairly solid position.

Understood. Last one, a short one.

Is the prepayments that have fallen, is it mainly Chinese customers that give you prepayments, and is the cash impact because of lower China orders?

Yes, it's the Chinese customers, and Chinese demand is not that strong, but there are some other institutes like your R&D institutes who make prepayments, but mainly from China customers.

Understood. Thank you very much.

Hi, guys. Thanks for taking my question.

I have a few. Just the first is on a slide you just showed on the different segments.

If I understand it correctly, you're saying the imaging is going to be kind of roughly flat, is coating, and then bonding is significantly higher than 2025. Then you've got your sales expectation down 10%.

I'm just trying to understand where exactly that weakness is coming from for that sales forecast. Thank you.

Madeleine, also a good question. Of course, the lower expectations, they stem from the accumulated order intake we collected in the last quarters.

From this, we can, of course, pre-calculate what we have already in our books. The rest, of course, are orders which we have to collect in the running year, mainly in Q1 and Q2 in '26.

Both together will, of course, create a forecast which we picked. We picked there a decline of 10% for both units because we see various effects, as I think detailed out in our presentation.

For photomask, it's the decline we saw from Chinese customers, and for the back end, it's really the combined effect of the low intake we have received so far. Now this trend, we see partially being now offsetted, but we need to know and, of course, experience how strong this new high order intake trend will last.

Perfect. Thank you.

Makes sense. My second question is just on HBM.

I think you mentioned in your opening remarks that only one of the customers was really in the Q4 order book. Do you have any indication of when the second customer might come in?

Also at your Investor Day, you mentioned the potential for qualification at SK Hynix. Could you provide an update on that as well, please?

As the other Korean customer still sits on a lot of underutilized equipment. We carefully planned in some kind of demand resuming in the second half of this year, but, of course, that has to materialize.

I have some good news on the other, the second Korean memory maker. There we did receive some HBM-related orders.

Basically, we can now claim that we are in all three major memory makers.

That's great. Thank you.

Just a final question quickly. On the wafer-to-wafer hybrid bonding side, there's a lot of talk recently on its kind of application in 4F-squared in DRAM.

I just wondered if you're kind of in any early conversations here. Do you expect to be selected as a supplier for this in the next few years as that transition is made?

Thank you.

Hybrid bonding, as Madeleine, is moving a bit sideways, a little bit away from die-to-wafer application because runways are extended for TCB bonding equipment and also some customers they are struggling with the process. Therefore, wafer-to-wafer hybrid bonding also comes in, because you can bond the wafers first and then do the die stacking.

I think there's some momentum going on there. I think it's still in a, I would say, more experimental phase where we do see some interest, but we haven't seen it materializing yet.

As you also know, we are not at the forefront with wafer-to-wafer hybrid bonders. There are two other suppliers ahead of us, but we have our systems at imec, where we are running tests and we can provide very good data.

I also expect more momentum picking up on that side also, where we can benefit from.

Perfect. Thank you very much.

Good afternoon. Thanks for taking my question.

Firstly, on the transition year again, maybe you could provide us with an update on, let's say, which of the products, the renewed products or the all-new products, you expect to contribute to sales first, what kind of ramp-up costs you expect, and whether you see, let's say, some cost portion that you incurred this year as kind of non-recurring, and also for the context of R&D, is that mostly on medium-term projects or is there also a bigger portion maybe including some external providers for, let's say, final engineering steps ahead of the product launches?

Michael, that's quite a mixed bag there. Let me start with the R&D side.

Yes, we have external and internal R&D, and I think we made very clear in our call here that we have not reduced our spend in R&D. In reverse, we increased the spending to make sure that we can stick to the launch timing of those products we have in our pipeline.

The first products are coming out this year, and there are notably three photomask products. One is the high-end mask cleaning, the MaskTrack Smart.

There we received the first order also in the first quarter of a large memory customer, and so that's the first shipment we are preparing for the second half of the year. The mid-end mask cleaners, we also there are working on the first systems because we have more than a handful of firm orders for that mid-end cleaner, which will replace also our aging mid-end platform, which we then take from the market.

The wafer cleaner, that's the third product, where also received first hardware, and we are doing our internal commissioning and evaluation before we send it to an launching customer. There are three products which are really in a final stage for roll-out this year.

Then there is a backend product, which is our UV scanner, which is panel capable at 310 by 310 projection scanner, which will be launched in Q3, also, of course, with a large Taiwanese target customer who already has set up a pilot line to evaluate the panel application. In that sense, four products which are launching this year.

Maybe we can squeeze in the fifth, but we have to see to get all these projects on the road. That's also the reason why we deliberately, yeah, in that sense, bit the bullet in high continued spend in R&D because we want to make sure we're not letting down the customers.

We anticipate therefore this gap or this drop in EBIT, but this is in our view just very short-term until we can reverse the trend.

Understood. Thank you.

Then maybe a follow-up in that context on wafer cleaning. At the CMD, you mentioned you're obviously starting with 200, but saw pretty strong demand also for 300 and also accelerate that project.

Where do we stand here in the timeline?

As you rightly said, the launching product is a 200 product. We want to, of course, get some feedback first, A, from our internal evaluation, and then, of course, also from the first customer feedback, which is then also an input for the design.

We're preparing the design phase for the 300 tool in combination with an external partner. We probably will kick off that design in the second half of this year, and we should see first hardware in the first half of 2027.

Understood. Thanks.

Then last one on the new UV scanner. My understanding is that the current product comes with a relatively low gross margin, should we expect the new product to be launched in Q3 to have a, let's say, sizable effect on the gross margin then, because it's probably a relatively big part of your top line right now?

Yes, that was the point in also redesigning this platform, which really came to age. Unfortunately, of course, the current CoWoS run couldn't wait for that.

That's why we have to ship the old version, and we probably have to keep doing so, because the first product we are launching is the panel version, which goes into a pilot line, and panel production is not going into volume until '28, '29 time frame. Very shortly after this panel version, of course, also our wafer version of the UV scanner, the next generation, is coming, but that launches in 2027.

That, of course, depending on the conversion rate, will then also improve this very low margin for the current TC.

All right. Understood.

Thank you.

Good afternoon. First one is on timing for potential photomask uptake in demand for photomask orders.

We have seen quite a strong Q4 order intake at ASML, obviously, with shipments mostly scheduled for 2027. Is that kind of supporting the assumption that you would expect an uptake in demand in the second half of this year for the photomask cleaning business?

Yes, Malte, that's a good assumption. Of course, we are loosely connected, because lead times and cycle times are very different if you compare us with an EUV system of ASML.

Ultimately, we should see these effects. As a matter of fact, we already see those effects because, despite our expected decline in China, we currently see even Chinese customers speeding up again, especially for photomask tools.

We also see international customers considering to pull in orders. We are in the middle of evaluating the impact of that.

That is a trend which started late in Q4 last year, and we see it continuing in this quarter, the running quarter.

Okay. For the Chinese demand you alluded to, is that then linked to the new mid-end cleaner, or would these customers still order the current equipment?

Actually, both. Of course, due to the equipment in use in China, the mid-end cleaner is more suitable for that market, but we see still a fairly high amount of high-end cleaning demand picking up again in China, which we didn't anticipate.

Okay. Quick one on Hynix.

Do you see or do you expect kind of more or less regular follow-up business when production lines get extended with the product you have placed at Hynix?

No, we're only interested in one-off sales, Malte. No, but I make a joke here.

Obviously, yes, that's the intent, to see follow-up business. I think for us it was important to get back into the door.

We're not talking volume orders here, but at least we have our hardware placed now in a recent HBM R&D line, which we can then, of course, exploit and hopefully get follow-up business.

Okay. Then on the guidance.

Given the current strength in orders that has continued into the first quarter of the year, the lower end of the guidance at the sales level, yeah, actually appears a bit low. Is that reflecting uncertainty at customer level you are recognizing, or is that rather linked to the overall global situation, which is not that stable at the moment?

Of course, one good quarter doesn't make a full year, as we all know. Although we really have a very strong expectation because the quarter is almost over for the first quarter in intake, we have to see how long this strong push remains.

When we created the guidance and also set our budgets, we had quite some expectations. There was also a certain concentration in the second half of the year.

Now we got strong demand already in the first quarter, and we have to see if this is continued trend because if the second half also remains strong, then, of course, we can come up with better results. Also the mix will have an important contribution here.

It's too early to just base it on one strong first quarter. In order intake, I must say, because in sales, we will not see a strong first quarter.

Sure. Okay.

Last one on double costs or one-offs which are baked into the earnings guidance for this year. Are you able to quantify an amount which is linked to double rents, ramp-up costs, and the like?

There are some one-offs regarding Taiwan, as because in the first quarter, we have some double rent, double cost, and, yeah, that's more or less what we included in our guidance.

That is a low single-digit amount?

Yes, it's €0.4 [million?] , something like this.

Thanks.

Thank you.

Yes, good afternoon. Also a couple of questions from my side.

Maybe let's first start with Taiwan, a short recap. How high was this payment you had made for the leasing which reduced the cash significantly?

Remind us, please, how high this impact was. How much capacity you have now finally in Taiwan?

Only to a reminder, because it gets more and more important.

Thomas speaking here. Hello, Johannes.

The investment in Taiwan was a low two-digit million-euro budget which we invested into the cleanrooms and all these kind of stuff. The leasing contract is now for 20 years

and

about €40 million of leasing agreement which we have there. The cash out is really only on a yearly base for sure, but the leasing has to be accounted in our books already for the complete period.

The capacity, only to really make this clear, we are really fully loading the factory as soon as possible. Right now, we have a load of around, let's say, about 70%, with the old sites which moved all into the new site, we are really heavily working on it to fill it up completely by at least the end of the year.

Mhm. Sorry, just want to add, as Thomas explained, of course, the leasing liability is booked, it's around €40 million, but you asked for cash out.

Cash out around €2 to €2.5 million this year. Okay.

Because the reduction in last year, what you mentioned partly, was the leasing a reason that the cash had come down heavily. That's a booking effect or?

Yes, it's KPI net cash figure, but it does not really says something about the duration of the liability in this case, it's just net cash. Cash out is over the 20 years.

Yeah. On the capacity, from a revenue, how much revenue you can handle with the capacity you have now in Taiwan?

I have something of €150-€200 million in my head, is that right, or?

That's a really good question, but it heavily depends on the product mix. As we are producing scanners there, coater, and bonders, and so from that point of view, it's really hard to say how much really revenue we can generate with this.

In general, I would say right now, because we have half-half between Germany and Taiwan, from that point of view, it's roughly perhaps the right order of magnitude, probably a little bit higher.

Okay. Half of the total revenue came already from Taiwan?

Not yet completely, but we are targeting for this.

Super. Thanks.

On the OSAT business, we hear from the OSATs that they are, ASE, that they definitely have heavily increased their budget. How much you have already seen in your own order income, and it's more to come in the coming quarters from this side?

Johannes, it's Burkhardt here. We already saw it last year, and I think I also mentioned that we saw this strong uptick for our coating and imaging business, which was mainly on the coating side contributed by additional demand from OSATs.

They're expanding in their existing sites in Asia, but also they are planning to expand in the US, as also some other companies are. There also we expect a continued strong demand.

You mentioned that the coating and imaging business, there's also scanner in, I know, which is low margin, but that's one region for the lower margin. I always in my head that the coating, at least coating, have a quite good margin.

Has it changed or is it only that maybe the scanner has just brought down this average margin of imaging and coating?

Coating is kind of pretty in the center of our margin distribution. It's not as good as the bonders, but by far not as bad as the UV scanners.

Okay. Thanks.

I expected this. Also for your forecast, you're expecting a stronger business with temporary bonding for this year, but the margin in Advanced Backend Solutions will nearly stay flat.

What is the reason, because last year it was the pressure coming partly from that the temporary bonding came down, now you expect an increase. Maybe we couldn't see a little bit stronger margin development in Advanced Backend?

It depends how many more orders we see, especially from the bonding side. When we set out these corridors, we assumed a certain mix.

We now see strong intake also on the bonder side. We have to see how sustainable this is, Johannes.

As I said, one good quarter doesn't make a full year. If the other Korean HBM maker doesn't place orders in the second half of this year, then I think we did everything right in our prognosis.

A lot of things can be happening, and as we saw last year, where we had to go in and correct twice our guidance, this is something we don't want to repeat.

It's clear. The bonding business is still above average at the margin side, yeah?

Yes, well above average.

Super. Last question, R&D, will it further increase this year, and only a feeling how much it could increase?

It will further increase, but how much?

Slightly.

It will increase only slightly. There are no big change really planned for this year, perhaps how much was it?

€2 or €3 million in total in absolute values. We try to keep the head count stable, also the investment in R&D.

Okay.

Maybe to add, Johannes, since the top line reduces, the R&D ratio increases even faster.

That's a fair point. Very fair point.

Finally now, because I will meet him in person in some weeks, but I think it's the last call maybe of Sven as IR, and I think maybe even in the name of all other participants, our all colleagues, I really want to say thanks a lot for his work and great support, and it was a pleasure to work with Sven.

Thank you so much, Johannes. It was my pleasure.

That's all. Thanks a lot.

Yes, hello. Good afternoon.

I had one follow-up on the UV projection scanner. I think you've provided already quite some indications, but I was looking for whether you were able to maybe quantify what the UV scanners actually contributed to the top line last year, and whether you could give us a sense of the 2026 order funnel, because there's many growth parameters out there.

I think in itself, this product could be quite sizable for you, not only this year, but in the next five years. It would be very helpful if we know a bit where you are currently.

It's, I think, fair to say that the revenue contribution of the UV scanner alone was between €30 and €40 million last year, and this year, this number will be larger.

Okay. All right, that's very helpful.

Then just thinking about your other let's say, younger product out there, thinking about the hybrid bonders, but also the inkjet printers, on a combined basis, are we thinking this is about 5% of sales in '26, or how should we think about that?

That is really a low contribution because we sold single units to customers who are evaluating those systems. This is not what I call a volume state.

We are at the very beginning of that. We had last year two, three systems we sold.

This year, we probably also have a couple of systems, but it's in a very single-digit percentage range. Okay.

Then

just for, yeah, the temporary bonder business, looking a bit further out, with HBM4E and HBM5 sort of requiring thinner dies and even more bonding complexity, are the existing platforms already compatible with those, let's say, next-generational stack requirements, or will there be a meaningful upgrade or new tool generation needed?

Our current generation of temporary bonders is, as we speak, qualified for HBM4, otherwise we wouldn't have received those orders. Of course, we are continuously improving our products and also listening to our customers, what else they need.

We have in parallel a flanking program to improve bond chamber performance to meet also future needs, because we are working both with the volume side of those customers, but also with their R&D centers, who already work on the next, N+1, N+2 generation of HBM stacks. We stay tuned, and then we work with our customers when are we phasing in which improvements.

It can be a running change, it can also be introduced in the next-generation platform. We do both.

I hope that helps.

Great. Then just a final question on I think co-packaged optics, you also talked about in the CMD, specifically on co-packaged optics on the interposer as a potential future opportunity.

In the last few months, excitement on co-packaged optics is quite strongly accelerated. My question is, within that further integration complexity, do I understand it well that basically your UV scanner and coating portfolio map well onto this, and what is generally the traction you've been seeing in the last 3 to 6 months on photonics in general?

You are absolutely right. There is a lot of hype there, and we are kind of positioned with our existing portfolio.

Of course, we need to enhance or upgrade our portfolio to also serve the co-package optics market well. It's from our side more kind of technical feasibility, what additional features are needed which can be added to our existing portfolio to also play a role there.

It's too early to really turn this into concrete products. Right now, it's on our side in an R&D development stage, and as soon as we have something not worthy to report, we will do so.

All right. Thank you very much.

Yes, thanks. One follow-up question on the orders in the first quarter of the year.

The environment is pretty dynamic, a continuation of the trend can have several meanings. Maybe some more color on what does it actually mean.

Typically Q1 is not the strongest quarter in terms of order intake, despite that fact, should we expect kind of more or less stable order development from the fourth quarter to the first quarter, which would be already good, or do you see even an acceleration? Some additional color would be appreciated.

I was almost fearing that this question will come, but it comes late now. I can confirm that we are breaking with that trend, that, in terms of order intake, this first quarter in '26 is a really very good quarter.

Since we are in the last two days of the quarter, of course, we already know what's coming, or we know most of it, and I can say that much that we will be well above the Q4 number of last year in terms of order intake.

Okay. Sounds good.

Thanks.

Yeah. Sorry.

Hello, everyone. I have a follow-up question regarding the sales forecast.

Maybe you can help me understand it better. Based on your order book of €267 million and assuming 18% of after-sales, your implied order intake needed in H1 to reach the midpoint is very, very modest, and you are saying that in Q1 order momentum was strong.

Of course, we need to have two strong quarters to complete the year because only what we have an intake in the first two quarters, the majority of that we can still turn around in products assembled, shipped, and recognized. The first quarter, if that is strong, that definitely helps to secure the guidance we provided.

If we have a second quarter which is also strong, that pretty much gives us some assurance that we are safe with that guidance. Again, this is speculation, I don't want to speculate.

I can only see a strong order momentum carried over from last quarter into the first quarter, and based on these two two quarters, we have made our sales projection.

Okay. Maybe correct me if I'm wrong.

Did you just mention that Q1 order intake is above Q4?

Yes, I did.

Okay. Wouldn't this already put you on the midpoint of guidance?

So €267 million plus €117 million, let's say, and 15% after even assuming conservative 15% after-sales, you are above guidance, or am I midpoint of guidance?

The €117 million of Q4 already included in the order book, I cannot follow your math there completely. Yes, of course, if we have a strong first quarter, that relieves some of the concerns because it's a continued reversal of the trend at a very high run rate.

If we can also get a decent second quarter in, then I would start agreeing with you, but we're not yet in the second quarter.

Maybe if I may add one sentence, the order book number of our annual report also always includes service business. If we get service business for example, a contract for two years, the entire period, this two years period is included in the total order book number.

Service is not getting on top completely, it's partially already included in order book.

I see. That's makes it clearer.

Thank you so much, Sven.

You're welcome.

I think ASML was late to the party to also join the backend business with their recent announcement and also their focus in that arena. They already have a scanner out there targeted for backend, but this one we don't see as a competition in the CoWoS process we are currently involved in.

However, that is, of course, competition for other markets. Our real competition, which is Canon, is facing.

That I don't see as a threat. The other activities, I think it's too early to gauge where this is heading.

Of course, there are other companies, whether it's AMAT or Lam and already TEL, who is already active in this domain. With ASML, this is just the last party, the last company joining the party.

I think this ultimately will just help the ecosystem to get on common ground here. I see this rather as an opportunity to collaborate than anything else.

My bad, that was a mistake.

Thank you so much, and nothing really to add. Take care, and yeah, get in touch if you have any more questions.

Thank you. Take care.